Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has acquired Coria Laboratories, a privately-held specialty pharmaceutical company focused on dermatology products in the US.
Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.
Comments